UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 10, 2017
WAVE LIFE SCIENCES LTD.
(Exact name of registrant as specified in its charter)
| | | | |
| Singapore | | 001-37627 | | Not Applicable |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| |
8 Cross Street#10-00, PWC Building Singapore 048424 | | 048424 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: +65 6236 3388
Check the appropriate box below if theForm 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant toRule 14a-12 under the Exchange Act (17 CFR240.14a-12) |
| ☐ | Pre-commencement communications pursuant toRule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant toRule 13e-4(c) under the Exchange Act (17 CFR240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 7.01 | Regulation FD Disclosure. |
On December 10, 2017, data from preclinical studies ofWVE-3972-01, Wave Life Sciences Ltd.’s (the “Company”) investigational stereopure antisense oligonucleotide designed to target the pathogenic allele of theC9ORF72 gene for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), were presented at the 28th International Symposium on ALS/MND. These data were presented by Robert Brown, Jr., DPhil, MD, with whom the Company is working in collaboration to further understand neurodegenerative and neuromuscular diseases, including ALS, and characterize the pharmacology of oligonucleotides. The slides presented containing these data are furnished as Exhibit 99.1 to this Current Report on Form8-K.
In addition, on December 11, 2017, the Company issued a press release announcing these data. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form8-K.
The information in Item 7.01 of this Current Report on Form8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
The following exhibits relating to Item 7.01 of this Current Report on Form8-K shall be deemed to be furnished and not filed:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | WAVE LIFE SCIENCES LTD. |
| | | |
| Date: December 11, 2017 | | | | | | /s/ Keith C. Regnante |
| | | | | | Keith C. Regnante |
| | | | | | Chief Financial Officer |
